GLS and neoplasm: By disrupting the high GLS/low GLUL mRNA expression pattern, the GLS inhibitor CB-839 induced an increase in tumor glutamine levels and a decrease in glutamate levels, ultimately causing significant tumor growth inhibition both in vitro and in vivo35.